ATLANTA, Aug. 23, 2012 /PRNewswire/ -- Alimera Sciences, Inc. (Nasdaq: ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Rick Eiswirth, Chief Operating Officer and Chief Financial Officer, will present at the Stifel Nicolaus Healthcare Conference at 3:15 P.M. ET on Thursday, September 6, 2012 in Boston, MA.
The presentation will be webcast live and can be accessed on the Investor Relations section of the corporate website at http://www.alimerasciences.com. For those who are not available to listen to the live broadcast, the webcast will be archived for 30 days.
About Alimera Sciences, Inc.
Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently Alimera is focused on diseases affecting the back of the eye, or retina. Its primary product, ILUVIEN, is an intravitreal implant containing fluocinolone acetonide (FAc), a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease.
|
ICR, LLC for Alimera Sciences John Mills 310-954-1105 |
SOURCE Alimera Sciences, Inc.